Biotec Pharmacon ASA
Cutting-edge biotechnology from Norway — Biotec Pharmacon.
Launch date
Employees
Market cap
€73.5m
Enterprise valuation
€54m (Public information from Sep 2024)
Share price
€1.46 B4V.F
Norway (HQ)
Financials
Estimates*
| NOK | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 77.2m | 93.4m | 128m | 137m | 119m |
| % growth | - | 21 % | 37 % | 7 % | (13 %) |
| EBITDA | (<1m) | 53.0m | 62.9m | 47.7m | 29.8m |
| % EBITDA margin | - | 57 % | 49 % | 35 % | 25 % |
| Profit | (6.4m) | 83.1m | 46.4m | 32.9m | 19.4m |
| % profit margin | (8 %) | 89 % | 36 % | 24 % | 16 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Biotec Pharmacon ASA
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.